Cristina Saura
Researcher Next ID · RN-035320
Researcher · Biochemistry, Genetics and Molecular Biology
Hebron, Spain
- Works count
- 786
- Citation count
- 20,297
- H-index
- 63
- i10-index
- 170
Research interests
Publications
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2407086
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2410858
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2404625
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer
New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2212856
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.08.017
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
Nature Communications · 2022 · https://doi.org/10.1038/s41467-022-32828-6
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2203690
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.019
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer
JAMA Oncology · 2021 · https://doi.org/10.1001/jamaoncol.2020.7932
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30465-4
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz177
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Nature · 2018 · https://doi.org/10.1038/nature25475
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy099
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
EMBO Molecular Medicine · 2018 · https://doi.org/10.15252/emmm.201809172
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30450-3
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu239
Current projects
No projects listed.